The 2016-2021 Outlook for Systemic Broad- And Medium-Spectrum Antibiotic Erythromycins in the United States
This specialized outlook examines systemic broad- and medium-spectrum antibiotic erythromycins in the United States during the 2016–2021 period. It is suited to readers seeking focused information on antibiotics, pharmaceutical markets, and the U.S. outlook for this product category.
About This Book
This publication examines the outlook for systemic broad- and medium-spectrum antibiotic erythromycins in the United States.
Its stated focus is the period from 2016 through 2021.
The title positions the work as a specialized resource for readers interested in antibiotics, pharmaceuticals, and the U.S. market.
Reviews
No reviews yet. Be the first to review this book!